Study Shows All siRNAs Have Anti-Angiogenic Property Associated with Immune Response

Despite raising questions about two siRNA-based drugs already in the clinic, the paper mostly reinforces what those in the RNAi field already knew: that RNA-based drugs have the potential to trigger unintended immune responses. Still, one industry player argues that the study results are flawed.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.